XML 43 R32.htm IDEA: XBRL DOCUMENT v3.25.3
Mergers, Acquisition of Opus Genetics (Details)
$ / shares in Units, $ in Millions
Oct. 22, 2024
USD ($)
Asset
$ / shares
shares
Sep. 30, 2025
shares
Apr. 30, 2025
shares
Dec. 31, 2024
shares
Acquisition of Opus Genetics [Abstract]        
Common stock, shares outstanding (in shares)   64,544,096   31,574,657
Preferred stock, shares outstanding (in shares)   0   0
Common Stock [Member] | Series A Preferred Stock [Member]        
Acquisition of Opus Genetics [Abstract]        
Number of shares issued upon conversion (in shares)     1,000  
Opus Genetics, Inc. [Member]        
Acquisition of Opus Genetics [Abstract]        
Common stock, shares outstanding (in shares) 31,435,507      
Preferred stock, shares outstanding (in shares) 14,145.374      
Purchase price | $ $ 25.8      
Number of asset acquired | Asset 1      
Opus Genetics, Inc. [Member] | Maximum [Member]        
Acquisition of Opus Genetics [Abstract]        
Percentage of underlying intellectual property associated with IRD therapies 90.00%      
Opus Genetics, Inc. [Member] | Series A Preferred Stock [Member]        
Acquisition of Opus Genetics [Abstract]        
Shares issued (in shares) 14,145.374      
Shares issued, price per share (in dollars per share) | $ / shares $ 0.0001      
Number of shares issued upon conversion (in shares) 1,000      
Opus Genetics, Inc. [Member] | Common Stock [Member]        
Acquisition of Opus Genetics [Abstract]        
Shares issued (in shares) 5,237,063      
Shares issued, price per share (in dollars per share) | $ / shares $ 0.0001